Chronic hypertension classification: Difference between revisions
Usama Talib (talk | contribs) |
Usama Talib (talk | contribs) |
||
Line 8: | Line 8: | ||
==Classification== | ==Classification== | ||
=== | ===JNC 8 update on JNC 7 Classification of Blood Pressure=== | ||
JNC8(2014) proposes no changes in the blood pressure classification given in JNC7(2004). According to the ''Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure''<ref name="jnc7">{{ | JNC8(2014) proposes no changes in the blood pressure classification given in JNC7(2004). According to the ''Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure''<ref name="jnc7">{{ | ||
cite journal | cite journal | ||
Line 23: | Line 23: | ||
{| border="0" style="border-collapse:collapse; text-align:center; font-size:120%;" cellpadding="5" align="center" width="600px" | {| border="0" style="border-collapse:collapse; text-align:center; font-size:120%;" cellpadding="5" align="center" width="600px" | ||
|- | |- | ||
|+ align="center" style="background:#4479BA; color: #FFFFFF;" |'''Blood Pressure Classification''' ||+ align="center" style="background:#4479BA; color: #FFFFFF;" |'''Systolic''' (mm Hg) ||bgcolor="#67e1ff"| ||+ align="center" style="background:#4479BA; color: #FFFFFF;" |'''Diastolic''' (mm Hg) | |+ align="center" style="background:#4479BA; color: #FFFFFF;" |'''Blood Pressure Classification''' | ||+ align="center" style="background:#4479BA; color: #FFFFFF;" |'''Systolic''' (mm Hg) ||bgcolor="#67e1ff"| ||+ align="center" style="background:#4479BA; color: #FFFFFF;" |'''Diastolic''' (mm Hg) | ||
|- | |- | ||
|bgcolor="#f3f3f3"|Normal|| < 120 || and ||< 80 | |bgcolor="#f3f3f3"|Normal|| < 120 || and ||< 80 | ||
Line 58: | Line 58: | ||
|} | |} | ||
===2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults ( | ===2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults (JNC 8) --''' DO NOT EDIT'''=== | ||
{| align=center | {| align=center | ||
|- | |- | ||
Line 70: | Line 70: | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|'''Methodology''' | |align="left" style="background:#DCDCDC;"|'''Methodology''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="left" | Nonsystematic literature review by expert committee including a | ||
range of study designs | range of study designs | ||
Recommendations based on consensus | Recommendations based on consensus | ||
| colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align="left" | Critical questions and review criteria defined by expert panel with | ||
input from methodology team | input from methodology team | ||
Line 86: | Line 86: | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|'''Definitions''' | |align="left" style="background:#DCDCDC;"|'''Definitions''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Defined hypertension and prehypertension | ||
| colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Definitions of hypertension and prehypertension not addressed, | ||
but thresholds for pharmacologic treatment were defined | but thresholds for pharmacologic treatment were defined | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|'''Treatment goals''' | |align="left" style="background:#DCDCDC;"|'''Treatment goals''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="left" | Separate treatment goals defined for “uncomplicated” hypertension | ||
and for subsets with various comorbid conditions | and for subsets with various comorbid conditions | ||
(diabetes and CKD) | (diabetes and CKD) | ||
| colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align="left" | Similar treatment goals defined for all hypertensive populations | ||
except when evidence review supports different goals for a particular | except when evidence review supports different goals for a particular | ||
Line 101: | Line 101: | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|'''Lifestyle recommendations''' | |align="left" style="background:#DCDCDC;"|'''Lifestyle recommendations''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Recommended lifestyle modifications based on literature review and | ||
expert opinion | expert opinion | ||
| colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Lifestyle modifications recommended by endorsing the evidencebased | ||
Recommendations of the Lifestyle Work Group | Recommendations of the Lifestyle Work Group | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|'''Drug therapy''' | |align="left" style="background:#DCDCDC;"|'''Drug therapy''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Recommended 5 classes to be considered as initial therapy but recommended | ||
thiazide-type diuretics as initial therapy for most patients | thiazide-type diuretics as initial therapy for most patients | ||
Line 121: | Line 121: | ||
names and usual dose ranges | names and usual dose ranges | ||
| colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align="left" | Recommended selection among 4 specific medication classes (ACEI | ||
or ARB, CCB or diuretics) and doses based on RCT evidence | or ARB, CCB or diuretics) and doses based on RCT evidence | ||
Line 131: | Line 131: | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|'''Scope of topics''' | |align="left" style="background:#DCDCDC;"|'''Scope of topics''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Addressed multiple issues (blood pressure measurement methods, | ||
patient evaluation components, secondary hypertension, adherence | patient evaluation components, secondary hypertension, adherence | ||
Line 137: | Line 137: | ||
populations) based on literature review and expert opinion | populations) based on literature review and expert opinion | ||
| colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Evidence review of RCTs addressed a limited number of questions, | ||
those judged by the panel to be of highest priority. | those judged by the panel to be of highest priority. | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|'''Pre-publication review''' | |align="left" style="background:#DCDCDC;"|'''Pre-publication review''' | ||
| colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="3" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Reviewed by the National High Blood Pressure Education Program | ||
Coordinating Committee, a coalition of 39 major professional, public, | Coordinating Committee, a coalition of 39 major professional, public, | ||
and voluntary organizations and 7 federal agencies | and voluntary organizations and 7 federal agencies | ||
| colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align=" | | colspan="4" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Reviewed by experts including those affiliated with professional and | ||
public organizations and federal agencies; no official sponsorship by | public organizations and federal agencies; no official sponsorship by | ||
Revision as of 19:55, 17 May 2017
Chronic Hypertension Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Chronic hypertension classification On the Web |
Directions to Hospitals Treating Chronic hypertension classification |
Risk calculators and risk factors for Chronic hypertension classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Assistant Editor-In-Chief: Yazan Daaboul, Serge Korjian, Usama Talib, BSc, MD [2]
Overview
In 2004, the Seventh Report of the Joint National Committee (JNC 7) classified blood pressure values into 4 categories: normal, prehypertension, stage I hypertension, and stage II hypertension.[1] In 2007, the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) classified blood pressure into 7 categories.[2] This classification remained unchanged in the 2013 ESH/ESC classification.[3] The ESH/ESC classification excludes JNC 7’s pre-hypertension category, but includes 3 different grades of hypertension in contrast to JNC 7’s two-stage classification of hypertension.
Classification
JNC 8 update on JNC 7 Classification of Blood Pressure
JNC8(2014) proposes no changes in the blood pressure classification given in JNC7(2004). According to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure[4] blood pressure values were classified as follows:
Normal | < 120 | and | < 80 |
Pre-Hypertension | 120-139 | or | 80-89 |
Stage 1 Hypertension | 140-159 | or | 90-99 |
Stage 2 Hypertension | >160 | or | >100 |
ESH/ESC Classification of Blood Pressure
In Europe, a different classification of blood pressure was introduced in 2007 by The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). According to the 2013 Guidelines for the Management of Arterial Hypertension, blood pressure values were classified as follows: [2]
Optimal | < 120 | and | < 80 |
Normal | 120-129 | and/or | 80-84 |
High Normal | 130-139 | and/or | 85-89 |
Grade 1 Hypertension | 140-159 | and/or | 90-99 |
Grade 2 Hypertension | 160-179 | and/or | 100-109 |
Grade 3 Hypertension | ≥ 180 | and/or | ≥110 |
Isolated Systolic Hypertension | ≥140 | and | <90 |
2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults (JNC 8) -- DO NOT EDIT
|
Abbreviations:
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; JNC, Joint National Committee;
RCT, randomized controlled trial.
Adopted from 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8).[5]
References
- ↑ Cuddy ML (2005). "Treatment of hypertension: guidelines from JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 1)". J Pract Nurs. 55 (4): 17–21, quiz 22-3. PMID 16512265.
- ↑ 2.0 2.1 Bonny A, Lacombe F, Yitemben M, Discazeaux B, Donetti J, Fahri P; et al. (2008). "The 2007 ESH/ESC guidelines for the management of arterial hypertension". J Hypertens. 26 (4): 825, author reply 825-6. doi:10.1097/HJH.0b013e3282f857e7. PMID 18327095.
- ↑ Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M; et al. (2013). "2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)". J Hypertens. 31 (7): 1281–357. doi:10.1097/01.hjh.0000431740.32696.cc. PMID 23817082.
- ↑ Chobanian AV; et al. (2003). "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report". JAMA. 289: 2560–72. PMID 12748199.
- ↑ James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J; et al. (2014). "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)". JAMA. 311 (5): 507–20. doi:10.1001/jama.2013.284427. PMID 24352797.